company background image
S66

Star Combo PharmaASX:S66 Stock Report

Market Cap

AU$42.5m

7D

10.5%

1Y

-8.7%

Updated

20 Oct, 2021

Data

Company Financials
S66 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

S66 Overview

Star Combo Pharma Limited engages in the manufacture and distribution of health food products and nutritional supplements in Australia and China.

Price History & Performance

Summary of all time highs, changes and price drops for Star Combo Pharma
Historical stock prices
Current Share PriceAU$0.32
52 Week HighAU$0.23
52 Week LowAU$0.40
Beta0.93
1 Month Change-7.35%
3 Month Change8.62%
1 Year Change-8.70%
3 Year Change-53.68%
5 Year Changen/a
Change since IPO-60.13%

Recent News & Updates

Mar 02
Star Combo Pharma's (ASX:S66) Robust Earnings Might Be Weaker Than You Think

Star Combo Pharma's (ASX:S66) Robust Earnings Might Be Weaker Than You Think

Shareholders didn't seem to be thrilled with Star Combo Pharma Limited's ( ASX:S66 ) recent earnings report, despite...

Shareholder Returns

S66AU Personal ProductsAU Market
7D10.5%1.0%1.7%
1Y-8.7%18.7%20.2%

Return vs Industry: S66 underperformed the Australian Personal Products industry which returned 18.7% over the past year.

Return vs Market: S66 underperformed the Australian Market which returned 20.2% over the past year.

Price Volatility

Is S66's price volatile compared to industry and market?
S66 volatility
S66 Beta0.93
Industry Beta0.70
Market Beta1

Stable Share Price: Insufficient data to determine S66's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine S66's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2004n/aSu Zhanghttps://www.starcombo.com.au

Star Combo Pharma Limited engages in the manufacture and distribution of health food products and nutritional supplements in Australia and China. The company operates through two segments, Star Combo and Austoyou Retail. It develops, manufactures, markets, and sells natural health supplements and skin care products.

Star Combo Pharma Fundamentals Summary

How do Star Combo Pharma's earnings and revenue compare to its market cap?
S66 fundamental statistics
Market CapAU$42.46m
Earnings (TTM)-AU$7.88m
Revenue (TTM)AU$26.97m

1.6x

P/S Ratio

-5.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
S66 income statement (TTM)
RevenueAU$26.97m
Cost of RevenueAU$23.54m
Gross ProfitAU$3.43m
ExpensesAU$11.31m
Earnings-AU$7.88m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.058
Gross Margin12.72%
Net Profit Margin-29.20%
Debt/Equity Ratio0.4%

How did S66 perform over the long term?

See historical performance and comparison

Valuation

Is Star Combo Pharma undervalued compared to its fair value and its price relative to the market?

1.17x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate S66's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate S66's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: S66 is unprofitable, so we can't compare its PE Ratio to the Global Personal Products industry average.

PE vs Market: S66 is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate S66's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: S66 is good value based on its PB Ratio (1.2x) compared to the AU Personal Products industry average (2.9x).


Future Growth

How is Star Combo Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.0%

Forecasted Household industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Star Combo Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Star Combo Pharma performed over the past 5 years?

-37.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: S66 is currently unprofitable.

Growing Profit Margin: S66 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: S66 is unprofitable, and losses have increased over the past 5 years at a rate of 37.4% per year.

Accelerating Growth: Unable to compare S66's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: S66 is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (23%).


Return on Equity

High ROE: S66 has a negative Return on Equity (-21.76%), as it is currently unprofitable.


Financial Health

How is Star Combo Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: S66's short term assets (A$26.4M) exceed its short term liabilities (A$3.5M).

Long Term Liabilities: S66's short term assets (A$26.4M) exceed its long term liabilities (A$3.6M).


Debt to Equity History and Analysis

Debt Level: S66's debt to equity ratio (0.4%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if S66's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: S66 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: S66 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 26.1% each year


Dividend

What is Star Combo Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate S66's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate S66's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if S66's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if S66's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of S66's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average board tenure


CEO

Su Zhang

no data

Tenure

AU$181,533

Compensation

Ms. Su Zhang, MBA, GradCertComm, BPharm serves as Chief Executive Officer at Star Combo Pharma Ltd since November 2018 and serves as its Executive Director since 2018. She served as Director at Star Combo...


CEO Compensation Analysis

Compensation vs Market: Su's total compensation ($USD135.73K) is below average for companies of similar size in the Australian market ($USD302.06K).

Compensation vs Earnings: Su's compensation has increased whilst the company is unprofitable.


Board Members

Experienced Board: S66's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Star Combo Pharma Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Star Combo Pharma Limited
  • Ticker: S66
  • Exchange: ASX
  • Founded: 2004
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: AU$42.460m
  • Shares outstanding: 134.79m
  • Website: https://www.starcombo.com.au

Location

  • Star Combo Pharma Limited
  • 171-177 Woodpark Road
  • Smithfield
  • New South Wales
  • 2164
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/20 07:05
End of Day Share Price2021/10/19 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.